In the past decade, there have been more than 120 psychedelic medicine trials worldwide, focusing on depression, anxiety, addiction, and PTSD. Up-to 80% of patients in these trials have gone into remission after just 2-3 small medicinal doses of MDMA or psilocybin, in tandem with psychotherapy. More recently, trials for psychedelic assisted psychotherapy for dementia and anorexia patients have yielded similar results (Mind Medicine Australia).
PACFA is excited to be partnered with Mind Medicine Australia for a free webinar for PACFA Members to help understand how psychedelic medicines work for a range of conditions, the implications for patients, ethical and legal considerations, and how the introduction of medicine-assisted psychotherapy will impact the Australian healthcare system. The webinar will take place on 25th August 2021, we will shortly be posting information on how to join so please check the events page of the PACFA website or the PACFA events bulletin email for details of how to participate.
PACFA is proud to be partnered with Mind Medicine Australia, who are working on ground-breaking research in the field of mental health, and advocating for better access to the best mental health treatments for Australians. For further information on Mind Medicine Australia, please visit their website here.